Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Phase 3

Conditions: Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage IA Uterine Corpus Cancer AJCC v7
Stage IB Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7
Stage II Uterine Corpus Cancer AJCC v7
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Internal Radiation Therapy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2009-07-20

Last Posted Date: 2021-10-19

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 813

Registration Number: NCT00942357

Locations: 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States

and more 663 locations

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-07-13

Last Posted Date: 2017-11-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 190

Registration Number: NCT00937560

Locations: 🇳🇱
Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde, Leidschendam, Netherlands
🇮🇹
Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Campobasso, Molise, Italy
🇫🇷
Clinique Tivoli; Sce Radiotherapie, Bordeaux, France

and more 51 locations

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary Origin

Interventions: Drug: carboplatin
Drug: everolimus
Drug: paclitaxel

First Posted Date: 2009-07-10

Last Posted Date: 2017-03-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 46

Registration Number: NCT00936702

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 136 locations

Lenalidomide and Paclitaxel in Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Lenalidomide
Drug: Paclitaxel

First Posted Date: 2009-07-07

Last Posted Date: 2016-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00933426

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: paclitaxel
Drug: RAD001

First Posted Date: 2009-07-07

Last Posted Date: 2015-03-18

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 28

Registration Number: NCT00933374

Locations: 🇩🇪
Heinrich-Heine-University of Duesseldorf, Department of Urology, Duesseldorf, NRW, Germany
🇩🇪
Klinik für Urologie, Universitätsklinikum Muenster, Muenster, NRW, Germany
🇩🇪
Universitätsklinik Hamburg, Medizinische Klinik und Poliklinik Onkologie - Hämatologie, Hamburg, Germany

and more 3 locations

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: cisplatin
Drug: everolimus
Drug: paclitaxel
Other: placebo
Procedure: Venous blood draw

First Posted Date: 2009-07-02

Last Posted Date: 2015-05-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 145

Registration Number: NCT00930930

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States

and more 5 locations

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Phase 2

Terminated

Conditions: Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy

Interventions: Drug: Paclitaxel
Drug: ZD4054 Zibotentan
Drug: Carboplatin
Drug: Placebo

First Posted Date: 2009-06-26

Last Posted Date: 2012-08-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 120

Registration Number: NCT00929162

Locations: 🇮🇹
Research Site, Roma, Italy

Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: carboplatin+ paclitaxel
Drug: paclitaxel

First Posted Date: 2009-06-12

Last Posted Date: 2014-08-15

Lead Sponsor: Tao OUYANG

Target Recruit Count: 148

Registration Number: NCT00919880

Locations: 🇨🇳
Beijing Cancer Hospital Breast Center, Beijing, Beijing, China

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Olaratumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-06-11

Last Posted Date: 2019-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 137

Registration Number: NCT00918203

Locations: 🇨🇦
ImClone Investigational Site, Edmonton, Alberta, Canada

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Everolimus
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2009-06-08

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 113

Registration Number: NCT00915603

Locations: 🇺🇸
Wilshire Oncology Medical Group, LaVerne, California, United States
🇺🇸
Mercy Hospital, Portland, Maine, United States
🇺🇸
Aventura Medical Center, Aventura, Florida, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy